You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia

https://doi.org/10.1136/annrheumdis-2020-217549

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors All authors have contributed to this manuscript and fulfil the requirements for authorship.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests PG has been a medical expert for LFB (Laboratoire Français du Biofractionnement) and has received fees from Abbvie, Actelion, Boehringer Ingelheim France, Bouchara-Recordati, Novartis, Pfizer and Roche in the last 5 years. ATJM has received fees from Abbvie, Actelion, CSL Behring, Experf, Novartis and Shire and declares speaking fees from Astra-Zeneca and BMS in the last 5 years.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles